Sargent Investment Group LLC Sells 1,359 Shares of MediWound Ltd. (NASDAQ:MDWD)

Sargent Investment Group LLC reduced its position in shares of MediWound Ltd. (NASDAQ:MDWD) by 1.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 117,192 shares of the biopharmaceutical company’s stock after selling 1,359 shares during the quarter. Sargent Investment Group LLC owned about 1.09% of MediWound worth $2,116,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in MDWD. Rhumbline Advisers acquired a new position in shares of MediWound in the second quarter worth about $131,000. Bank of New York Mellon Corp purchased a new stake in shares of MediWound in the 2nd quarter valued at approximately $342,000. Janney Montgomery Scott LLC purchased a new stake in shares of MediWound in the 1st quarter valued at approximately $427,000. ARK Investment Management LLC purchased a new position in shares of MediWound during the 3rd quarter worth approximately $1,806,000. Finally, Rosalind Advisors Inc. boosted its position in shares of MediWound by 5.7% during the 2nd quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company’s stock worth $7,969,000 after purchasing an additional 27,500 shares during the period. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Stock Performance

MediWound stock traded down $0.02 during trading on Thursday, reaching $16.58. 11,008 shares of the company’s stock were exchanged, compared to its average volume of 90,610. The company’s 50-day moving average is $17.33 and its two-hundred day moving average is $17.52. MediWound Ltd. has a 52-week low of $7.74 and a 52-week high of $24.00. The firm has a market cap of $178.90 million, a price-to-earnings ratio of -7.68 and a beta of 0.83.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.26). The firm had revenue of $5.06 million during the quarter, compared to analysts’ expectations of $5.07 million. MediWound had a negative net margin of 99.17% and a negative return on equity of 52.49%. Analysts anticipate that MediWound Ltd. will post -2.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on MDWD shares. StockNews.com upgraded shares of MediWound to a “sell” rating in a report on Monday, August 5th. HC Wainwright reiterated a “buy” rating and set a $28.00 price target on shares of MediWound in a research note on Friday, October 11th.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.